Short-Term Benefits for Immunothx in Allergic Asthma

This article originally appeared here.
Share this content:
Short-Term Benefits for Immunothx in Allergic Asthma
Short-Term Benefits for Immunothx in Allergic Asthma

FRIDAY, June 2, 2017 (HealthDay News) -- Administration of allergen immunotherapy (AIT) in patients with allergic asthma leads to lower short-term symptom and medication scores, according to a review published online May 19 in Allergy.

Sangeeta Dhami, M.B.B.S., from Evidence-Based Health Care in Edinburgh, U.K., and colleagues performed a systematic review to examine evidence on the effectiveness, cost-effectiveness, and safety of AIT. Data were reviewed from 98 studies.

The researchers observed a reduction in short-term symptom and medication scores, with evidence found for publication bias. No reduction was seen in short-term combined medication and symptom scores; a beneficial long-term effect was seen in one study. Subcutaneous immunotherapy correlated with improved quality of life and reduction in allergen-specific airway hyperreactivity (AHR); this was not seen for sublingual immunotherapy (SLIT). No consistent effects were seen on asthma control, exacerbations, lung function, or non-specific AHR. There was a modest increase in the risk of adverse events with AIT. Evidence on cost-effectiveness was mainly available for SLIT, which was likely to be cost-effective.

"AIT can achieve substantial reductions in short-term symptom and medication scores in allergic asthma," the authors write. "More data are needed in relation to secondary outcomes, longer-term effectiveness, and cost-effectiveness."

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Zika Does Not Appear to Last in Semen As Long As Thought

Zika Does Not Appear to Last in Semen ...

More research is needed to better inform public health recommendations

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke Risk

Radioiodine Therapy for Thyroid Cancer Doesn't Up Stroke ...

I-131 therapy group showed no significantly higher risk of ischemic or hemorrhagic stroke

Higher Odds of Infection With Reduced Kidney Function

Higher Odds of Infection With Reduced Kidney Function

Study finds excess community-acquired infections incidence in individuals with mild to severe CKD

is free, fast, and customized just for you!

Already a member?

Sign In Now »